fluticasone furoate; vilanterol trifenatate: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275	NDA	GlaxoSmithKline LLC	0173-0859-10	1 TRAY in 1 CARTON (0173-0859-10) / 1 INHALER in 1 TRAY / 30 POWDER in 1 INHALER	2013-08-26
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275	NDA	GlaxoSmithKline LLC	0173-0859-14	1 TRAY in 1 CARTON (0173-0859-14) / 1 INHALER in 1 TRAY / 14 POWDER in 1 INHALER	2013-08-26
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275	NDA	GlaxoSmithKline LLC	0173-0882-10	1 TRAY in 1 CARTON (0173-0882-10) / 1 INHALER in 1 TRAY / 30 POWDER in 1 INHALER	2015-04-30
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275	NDA	GlaxoSmithKline LLC	0173-0882-14	1 TRAY in 1 CARTON (0173-0882-14) / 1 INHALER in 1 TRAY / 14 POWDER in 1 INHALER	2015-04-30
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275	NDA	GlaxoSmithKline LLC	0173-0916-10	1 TRAY in 1 CARTON (0173-0916-10) / 1 INHALER in 1 TRAY / 30 POWDER in 1 INHALER	2023-05-12
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275	NDA AUTHORIZED GENERIC	Prasco Laboratories	66993-135-97	1 TRAY in 1 CARTON (66993-135-97) / 1 INHALER in 1 TRAY / 30 POWDER in 1 INHALER	2022-05-23
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the supply chain for FLUTICASONE FUROATE (FF) and VILANTEROL TRIFENATATE (VT), the active pharmaceutical ingredients (APIs) in the combination inhaler product. Key suppliers of critical raw materials, intermediates, and API manufacturing services are identified, alongside regulatory considerations and market dynamics impacting this segment of the respiratory drug market.

Who Are the Primary API Manufacturers for FLUTICASONE FUROATE and VILANTEROL TRIFENATATE?

The production of FLUTICASONE FUROATE (FF) and VILANTEROL TRIFENATATE (VT) involves complex multi-step chemical synthesis. While specific contract manufacturers are often proprietary information, analysis of patent filings, regulatory submissions, and industry reports indicates a concentration of manufacturing expertise among a select group of global pharmaceutical ingredient suppliers and Contract Development and Manufacturing Organizations (CDMOs).

The primary manufacturers are typically those with established capabilities in steroid chemistry for FF and in complex organic synthesis for VT. These entities possess the necessary infrastructure for Good Manufacturing Practice (GMP) compliance, stringent quality control, and large-scale API production.

Companies with significant expertise in corticosteroid synthesis are primary candidates for FF production. This includes companies that have historically supplied corticosteroids for other inhalation products. Similarly, VT, a long-acting beta2-adrenergic agonist (LABA), requires specialized synthesis capabilities for its chiral centers and specific chemical structure.

Key Manufacturing Capabilities Required:

Steroid Synthesis: For FLUTICASONE FUROATE, this involves precise control over multi-step functionalization of steroid cores, including esterification and halogenation.
Chiral Synthesis and Purification: For VILANTEROL TRIFENATATE, the synthesis of specific enantiomers with high purity is critical, requiring expertise in asymmetric synthesis and enantioselective catalysis.
Particle Engineering and Micronization: Post-synthesis, APIs for inhalation products undergo critical processing to achieve specific particle size distributions necessary for pulmonary delivery. This requires specialized micronization techniques, such as jet milling.
GMP Compliance: All manufacturing processes must adhere to strict GMP standards set by regulatory authorities like the FDA, EMA, and others. This includes rigorous process validation, quality assurance, and documentation.

Companies operating in this space are often large, established chemical and pharmaceutical manufacturers or specialized CDMOs. Due to the proprietary nature of API manufacturing contracts, publicly available lists of direct suppliers for these specific APIs are limited. However, industry analysis points to major players with broad portfolios in respiratory APIs and complex organic synthesis.

What Are the Key Raw Materials and Intermediates for Each API?

The synthesis of both FLUTICASONE FUROATE and VILANTEROL TRIFENATATE is a multi-stage process involving numerous chemical reactions and purification steps. Each API requires a distinct set of starting materials and intermediates.

FLUTICASONE FUROATE (FF)

The synthesis of FF is rooted in corticosteroid chemistry. Key starting materials and intermediates often derive from steroidal precursors.

Starting Material Precursors: While the precise proprietary starting materials vary between manufacturers, common steroid skeletons are utilized. These can include derivatives of androstenedione or similar structures.
Key Intermediates:
- 17α-hydroxypregnenolone derivatives: These are often early-stage intermediates in the synthesis of corticosteroids.
- Halogenated steroid intermediates: Introduction of fluorine at the C6α and C9α positions and chlorine at C11β are critical steps.
- Functionalized steroid cores: Intermediates bearing hydroxyl groups at C17 and C21, which are subsequently esterified.
- Furoyl chloride or furoic acid: Used for the esterification of the C17 hydroxyl group.
Reagents and Solvents: Common reagents include halogenating agents (e.g., N-chlorosuccinimide, N-fluorobenzenesulfonimide), oxidizing agents, reducing agents, esterification catalysts, and a range of organic solvents (e.g., dichloromethane, tetrahydrofuran, ethyl acetate).

VILANTEROL TRIFENATATE (VT)

VT is a LABA requiring complex organic synthesis, often involving the formation of an ether linkage and the introduction of a chiral center.

Starting Material Precursors: Synthesis typically begins with simpler aromatic or heterocyclic compounds.
- Substituted phenylacetic acids or related structures: These can serve as a basis for building the molecule.
- Amines and alkyl halides: Used for coupling reactions to build the carbon skeleton.
Key Intermediates:
- Chiral epoxides or alcohols: Critical for introducing the specific stereochemistry at the benzylic hydroxyl position.
- Phenol derivatives with specific substitution patterns: Used to form the ether linkage.
- Amine intermediates: Containing the characteristic side chain structure, which is then coupled with the other half of the molecule.
- Protected functional groups: To prevent unwanted reactions during synthesis.
Reagents and Solvents: This includes coupling reagents (e.g., palladium catalysts for cross-coupling), chiral catalysts or resolving agents, bases (e.g., potassium carbonate, triethylamine), acids, and various organic solvents. The trifenatate salt form (triphenylacetic acid) is a final component added in the salt formation step.

The supply chain for these raw materials and intermediates is global, involving specialized chemical manufacturers that focus on producing these complex organic molecules at scale and with high purity. Sourcing these materials requires robust supplier qualification processes to ensure quality, reliability, and regulatory compliance.

What Are the Regulatory Considerations for Manufacturing and Supply?

The manufacture of FLUTICASONE FUROATE (FF) and VILANTEROL TRIFENATATE (VT), like all pharmaceutical APIs, is subject to stringent regulatory oversight by health authorities worldwide. Compliance with Good Manufacturing Practices (GMP) is paramount.

Key Regulatory Aspects:

Good Manufacturing Practices (GMP):
- FDA (U.S. Food and Drug Administration): Manufacturers must comply with 21 CFR Part 210 and 211.
- EMA (European Medicines Agency): Adherence to EudraLex Volume 4 is required.
- ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines, such as ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), are globally adopted. This covers quality management, personnel, buildings and facilities, process equipment, documentation, materials management, production and in-process controls, packaging and labeling, and storage and distribution.
Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the chemistry, manufacturing, and controls (CMC) of the API. Pharmaceutical companies refer to these DMFs in their drug product marketing applications.
Quality Control and Assurance:
- Rigorous testing of raw materials, intermediates, and finished APIs is mandatory. This includes identity, purity, potency, and impurity profiling.
- Validation of analytical methods used for testing.
- Stability testing to determine shelf-life and storage conditions.
Impurity Profiling and Control:
- Identification, qualification, and control of process-related impurities and degradants are critical. Specific limits are set by ICH Q3A (Impurities in New Drug Substances) and Q3B (Impurities in New Drug Products).
- Control of genotoxic impurities is a significant focus.
Supply Chain Integrity:
- Ensuring the security and traceability of the supply chain from raw materials to the final API.
- Supplier qualification and auditing are essential to ensure the quality and reliability of raw material and intermediate suppliers.
Change Control: Any changes to the manufacturing process, equipment, or materials must be evaluated, documented, and, if necessary, reported to regulatory authorities.
Environmental, Health, and Safety (EHS) Regulations: Manufacturing facilities must comply with local and international EHS standards related to chemical handling, waste disposal, and worker safety.

For inhalation products, additional considerations may include control of particle size distribution, polymorphs, and residual solvents, as these can impact drug product performance and safety. The trifenatate salt of vilanterol also requires specific control over its crystalline form.

What Are the Key Suppliers of Critical Raw Materials and Intermediates?

Identifying specific suppliers for the numerous raw materials and intermediates used in the synthesis of FLUTICASONE FUROATE (FF) and VILANTEROL TRIFENATATE (VT) is challenging due to the proprietary nature of pharmaceutical supply chains. However, the types of companies involved and the geographic regions where these materials are sourced can be characterized. These suppliers are typically specialized fine chemical manufacturers, rather than large pharmaceutical companies themselves.

General Categories of Suppliers:

Specialty Chemical Manufacturers: Companies focusing on the production of advanced intermediates, chiral building blocks, and reagents for the pharmaceutical industry. These suppliers often have expertise in specific chemical transformations.
Generic API Manufacturers: Some large generic API manufacturers may also produce key intermediates for proprietary drugs, particularly if they have strong backward integration capabilities.
Contract Manufacturing Organizations (CMOs) / Contract Development and Manufacturing Organizations (CDMOs): While primarily known for API synthesis, some CDMOs also offer custom synthesis of critical intermediates.
Regional Specialization:
- China and India: These countries are significant global suppliers of a broad range of chemical intermediates and raw materials due to cost competitiveness and extensive manufacturing infrastructure. Many key starting materials and early-stage intermediates are likely sourced from these regions.
- Europe and North America: Manufacturers in these regions often focus on higher-value, more complex intermediates, chiral compounds, or materials requiring highly specialized synthesis or stringent quality control. They may also be preferred for certain materials due to regulatory familiarity or intellectual property considerations.

Examples of Intermediate Types and Potential Supplier Profiles:

Steroid Precursors (for FF): Companies with established steroid chemistry expertise, often in India and China, are key suppliers.
Chiral Building Blocks (for VT): Manufacturers specializing in asymmetric synthesis and the production of enantiomerically pure compounds are critical. This includes companies offering chiral amines, alcohols, or epoxides.
Halogenated Compounds (for FF): Companies with strong capabilities in fluorination and chlorination chemistry.
Aromatic and Heterocyclic Building Blocks (for VT): Broad-based fine chemical suppliers.
Specialized Reagents: Suppliers of catalysts, protecting groups, and other advanced synthetic reagents.

Supplier Due Diligence:

Pharmaceutical companies rigorously vet their suppliers. This includes:

Quality Audits: Assessing the supplier's GMP compliance, quality systems, and manufacturing processes.
Technical Capabilities: Verifying the supplier's ability to produce the required materials with consistent quality and yield.
Regulatory Compliance: Ensuring suppliers meet relevant EHS and international regulatory standards.
Supply Chain Security: Implementing measures to prevent counterfeiting and ensure traceability.
Financial Stability: Assessing the supplier's reliability as a long-term partner.

Due to the competitive and confidential nature of this sector, naming specific companies without direct confirmation is speculative. However, the supply chain relies on a network of highly specialized chemical manufacturers that can reliably produce these complex molecules under strict quality controls.

What Is the Market Landscape for FLUTICASONE FUROATE and VILANTEROL TRIFENATATE APIs?

The market for FLUTICASONE FUROATE (FF) and VILANTEROL TRIFENATATE (VT) APIs is driven by the demand for combination inhaler products used in the treatment of respiratory diseases, primarily Chronic Obstructive Pulmonary Disease (COPD) and asthma.

Market Dynamics:

Branded Product Dominance: The primary combination product utilizing these APIs is Advair/Seretide (though Advair uses fluticasone propionate, not furoate, Seretide is a better comparison for this API combination). Correction: The combination of FLUTICASONE FUROATE and VILANTEROL TRIFENATATE is marketed under brands like Breo Ellipta/Relvar Ellipta. Advair/Seretide uses fluticasone propionate and salmeterol. The market for these branded products is substantial, creating a consistent demand for the APIs.
Patent Expirations and Generic Entry: As patents for the branded combination products approach expiration, the market for generic versions of FF and VT APIs is expected to grow. This creates opportunities for generic API manufacturers and CDMOs capable of producing these complex molecules cost-effectively and to high-quality standards.
- Patents for the innovator products play a significant role in market exclusivity. For example, patents related to the specific salt forms, crystalline structures, or manufacturing processes can extend market protection.
Competitive Landscape for API Manufacturers: The production of FF and VT requires specialized chemical synthesis capabilities and significant investment in GMP-compliant facilities. This limits the number of qualified API manufacturers.
- The market includes both large, established pharmaceutical ingredient suppliers and specialized CDMOs.
- Key competitive factors include cost of production, quality and regulatory compliance, reliability of supply, and intellectual property (IP) landscape.
Geographic Concentration of Manufacturing: As noted, a significant portion of intermediate and API manufacturing occurs in Asia, particularly China and India, due to cost advantages. However, concerns around supply chain resilience and quality may lead some pharmaceutical companies to diversify their sourcing to include manufacturers in Europe and North America.
Technological Advancements: Ongoing research and development in API manufacturing processes aim to improve yields, reduce costs, and minimize environmental impact. This can include advancements in catalysis, continuous manufacturing, and novel purification techniques.
Regulatory Hurdles for Generic Entry: The complexity of the synthesis and the rigorous regulatory requirements for inhalation APIs mean that generic entry is often a lengthy and capital-intensive process. Generic API manufacturers must demonstrate bioequivalence and manufacturing equivalence to the innovator product.
Market Size and Growth: The global market for respiratory drugs is substantial and projected to grow, driven by an aging population, increasing prevalence of respiratory diseases, and improving diagnostic capabilities. This translates to sustained demand for key APIs like FF and VT.

Key Trends:

Increased focus on supply chain security and resilience: Geopolitical events and the COVID-19 pandemic have highlighted the risks associated with highly concentrated supply chains.
Growing demand for high-purity APIs: Regulatory scrutiny on impurities, especially genotoxic ones, continues to increase.
Shift towards sustainability in manufacturing: Pressure to adopt greener chemistry and reduce environmental footprints is growing.

The market for FF and VT APIs is therefore characterized by a balance between the stability of branded product demand and the emerging opportunities and challenges presented by generic competition, all within a highly regulated and technically demanding manufacturing environment.

Key Takeaways

Manufacturing of FLUTICASONE FUROATE (FF) and VILANTEROL TRIFENATATE (VT) APIs requires advanced capabilities in steroid chemistry and complex organic synthesis, respectively.
Key raw materials and intermediates are sourced globally, with significant production capacity concentrated in China and India for cost-effectiveness, and specialized or higher-value intermediates potentially sourced from Europe and North America.
All API manufacturing must adhere to stringent GMP regulations enforced by global health authorities (FDA, EMA), necessitating comprehensive quality control, impurity profiling, and robust supply chain management.
The market for FF and VT APIs is driven by demand for branded respiratory combination inhalers, with significant growth potential anticipated from generic market entry as patents expire.
Competitive differentiation among API suppliers hinges on manufacturing cost, quality, regulatory compliance, supply chain reliability, and IP position.

Frequently Asked Questions

What are the typical particle size specifications for FLUTICASONE FUROATE and VILANTEROL TRIFENATATE used in inhalers? Particle size distribution for inhaled APIs is critical for effective lung deposition. While specific specifications are proprietary and vary by product formulation, typical ranges for micronized APIs are often between 1-5 micrometers (geometric mean diameter), with a narrow distribution to ensure consistent delivery.
Are there specific challenges in the synthesis of VILANTEROL TRIFENATATE compared to FLUTICASONE FUROATE? Yes, VILANTEROL TRIFENATATE presents challenges primarily due to the requirement for stereospecific synthesis to achieve the correct enantiomer, which necessitates expertise in chiral chemistry and potentially enantioselective catalysis or resolution techniques. FLUTICASONE FUROATE's synthesis is complex due to its multi-step steroid functionalization and halogenation, but does not inherently involve stereochemical challenges at the same level as VT.
How do regulatory agencies assess the quality of API suppliers? Regulatory agencies conduct on-site GMP inspections of API manufacturing facilities, review Drug Master Files (DMFs) for detailed CMC information, and evaluate a company's quality management system. Supplier qualification by the drug product manufacturer, including audits, is also a critical part of the regulatory oversight process.
What is the impact of patent expiry on the market for these APIs? Patent expiry for the innovator combination drug products opens the door for generic competition. This typically leads to increased demand for the APIs from generic manufacturers and can drive down API prices due to increased competition among API suppliers. However, the complexity of these APIs means generic entry can still be challenging.
What is the significance of the trifenatate salt for vilanterol? The trifenatate salt form of vilanterol is specifically chosen to optimize properties such as stability, solubility, and potentially crystallinity, which are crucial for the formulation of the inhaled product and its pharmacokinetic profile. The salt formation is a critical step in the API manufacturing process.

Citations

[1] U.S. Food and Drug Administration. (2023). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from [FDA Website (specific URL not provided as it's a general regulation link)] [2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Retrieved from [EMA Website (specific URL not provided as it's a general regulation link)] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2000). ICH Harmonised Tripartite Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline Q3A(R2): Impurities in New Drug Substances. [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2017). ICH Harmonised Tripartite Guideline Q3B(R2): Impurities in New Drug Products.

Suppliers and packagers for generic pharmaceutical drug: fluticasone furoate; vilanterol trifenatate